NCT02837445 - Moderato System: A Double-Blind Randomized Trial Ver 1.1 | Biotech Hunter

Enrollment

170

Participants

Timeline

Start Date

July 12, 2016

Primary Completion Date

August 31, 2019

Study Completion Date

March 31, 2023

Conditions

Hypertension Resistant to Conventional TherapyBradycardiaAtrioventricular Block

Interventions

DEVICE

PHC ON

Eligible patients randomized after optimization phase to PHC ON for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator

DEVICE

PHC OFF

Eligible patients randomized after optimization phase to PHC OFF for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.

Trial Locations (12)

1002

P. Stradins Clinical University Hospital, Riga

1090

Medical University Vienna, Vienna

UZ Brussel - Heart Rhythm Management Center, Brussels

1122

Semmelweis University Heart and Vascular Center, Budapest

4020

Krankenhaus der Elisabethinen, Linz

15030

Na Homolce Hospital, Prague

08661

Vilnius University Hospital Santariskiu Klinikos, Vilnius

80-952

Medical University of Gdansk, Gdansk

61-848

Szpital Kliniczny Przemiemienia Panskiego, Poznan

70-111

Pomeranian Medical University Hospital no. 2, Szczecin

02-097

Samodzielnym Publicznym Centralnym Szpitalem Klinicznym, Warsaw

41-800

Silesian Center for Heart Diseases, Zabrze